mRNA-1273

mRNA-1273
Name	mRNA-1273
Type	mRNA
Target	Severe acute respiratory syndrome coronavirus 2
Developer	Moderna
Manufacturer	Moderna, Lonza
Route	Intramuscular
Authorised	2020

mRNA-1273 is a messenger RNA vaccine developed to prevent disease caused by Severe acute respiratory syndrome coronavirus 2. It was created through collaboration among Moderna, the National Institute of Allergy and Infectious Diseases, and contract manufacturing partners during the COVID-19 pandemic. The vaccine became a focal point of public health campaigns, mass vaccination programs, and regulatory review across multiple countries.

Background and Development

Development of mRNA-1273 began after the identification of Severe acute respiratory syndrome coronavirus 2 in Wuhan, with early contributions from Moderna and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases. Preclinical work involved institutions such as the National Institutes of Health, the Biomedical Advanced Research and Development Authority, and academic laboratories at Harvard University and the University of Pennsylvania. Clinical development proceeded through partnerships with contract research organizations, manufacturing collaborations with Lonza, and funding from Operation Warp Speed and other governmental initiatives. The project intersected with global responses involving the World Health Organization, the European Commission, and national agencies like the Food and Drug Administration and Health Canada.

Composition and Mechanism of Action

mRNA-1273 comprises nucleoside-modified messenger RNA encapsulated in lipid nanoparticles manufactured by companies including Moderna and Lonza. The sequence encodes a stabilized prefusion form of the coronavirus spike protein, designed using knowledge from structural biology centers at the Scripps Research Institute and the University of Oxford. Lipid components resemble proprietary formulations informed by collaborations with vendors and regulatory dossiers submitted to agencies such as the European Medicines Agency. Upon intramuscular administration, host cells in muscle and draining lymph nodes express the spike protein, engaging antigen-presenting cells, dendritic cells characterized in studies at Rockefeller University, and lymphoid tissues like the spleen and lymph nodes described in work at Johns Hopkins University. This expression stimulates B cell responses in germinal centers studied at Yale University and T cell responses observed in immunology research at Stanford University, leading to neutralizing antibodies documented in assays used by academic centers including the Broad Institute and the Fred Hutchinson Cancer Center.

Clinical Trials and Efficacy

Phase 1, 2, and 3 trials were conducted across academic medical centers such as Massachusetts General Hospital, the University of California, San Diego, and Emory University, with regulatory oversight by the Food and Drug Administration and ethics review boards at institutions like Columbia University. The pivotal Phase 3 trial, entitled COVE, enrolled tens of thousands of participants at sites coordinated by investigators affiliated with Cleveland Clinic, Mayo Clinic, and University of Miami. Efficacy analyses referenced outcomes including symptomatic COVID-19, severe disease, and hospitalization, and were compared with contemporaneous vaccine trials from Pfizer–BioNTech, AstraZeneca, and Johnson & Johnson. Results influenced policy decisions by the Centers for Disease Control and Prevention, Public Health England, and Santé publique France.

Safety, Adverse Effects, and Contraindications

Safety monitoring involved pharmacovigilance systems such as the Vaccine Adverse Event Reporting System and electronic health record analyses at Kaiser Permanente and Veterans Health Administration. Common local and systemic reactions were recorded at clinical trial sites including Northwestern University and the University of Colorado, while rare events prompted investigations by advisory committees at the Food and Drug Administration, the Advisory Committee on Immunization Practices, and the European Medicines Agency. Reported serious adverse events were evaluated by expert panels including representatives from the American College of Cardiology and the American Academy of Pediatrics. Contraindications and precautions were incorporated into guidance from professional societies such as the American Medical Association and the Infectious Diseases Society of America.

Manufacturing, Storage, and Distribution

Large-scale manufacturing involved Moderna, Lonza, and contract manufacturers across sites in the United States and Switzerland, coordinated with distribution channels used by logistics firms and supply chains stressed during global vaccination campaigns similar to those managed by UPS and DHL. Cold-chain requirements influenced storage recommendations issued by the Centers for Disease Control and Prevention and the European Centre for Disease Prevention and Control, and were addressed using refrigeration equipment suppliers and hospital pharmacy networks at institutions such as Mount Sinai and Cleveland Clinic. Dose-sparing strategies and booster policies were debated in the context of global initiatives led by COVAX and the Coalition for Epidemic Preparedness Innovations.

Regulatory Approval and Emergency Use

Regulatory actions included Emergency Use Authorization and conditional marketing authorizations by agencies such as the Food and Drug Administration, the European Medicines Agency, Health Canada, and the Medicines and Healthcare products Regulatory Agency. Advisory hearings involved expert testimony from investigators at the National Institutes of Health, legal review by offices within the Department of Health and Human Services, and deliberations by committees like the Vaccines and Related Biological Products Advisory Committee. Approvals were aligned with contemporaneous authorizations for vaccines from Pfizer–BioNTech, AstraZeneca, and Sinopharm, and shaped by guidance from the World Health Organization.

Public Health Impact and Uptake

mRNA-1273 became central to immunization campaigns led by national programs in the United States, United Kingdom, Israel, and Germany, influencing hospitalization rates monitored by agencies such as the Centers for Disease Control and Prevention and Public Health England. Uptake varied across populations studied by researchers at Harvard T.H. Chan School of Public Health, the London School of Hygiene & Tropical Medicine, and the University of Toronto, with disparities examined in work by WHO, UNICEF, and the Pan American Health Organization. Debates over booster policies, international allocation, and vaccine equity engaged stakeholders including Gavi, national ministries of health, and nongovernmental organizations active in global health.

Category:Vaccines